Compositions and methods for treating pain disorders

By administering recombinant or synthetic AIBP polypeptides that bind to TLR4, the formulation effectively addresses the inadequacies of current pain treatments by reducing TLR4-mediated inflammation and providing substantial pain relief for pain-associated diseases and conditions.

WO2025076208A9 Publication Date: 2025-06-19RAFT PHARMACEUTICALS INC +1
0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/049774
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-03
Filing Date
2024-10-03
Publication Date
2025-06-19

AI Technical Summary

Technical Problem

Current treatments for pain-associated diseases and conditions, such as neuropathic pain, CNS inflammation, and primary headaches, are inadequate, leading to significant healthcare challenges due to their limited efficacy and prolonged duration of pain relief.

Method used

Administration of a pharmaceutically acceptable formulation comprising a recombinant or synthetic ApoA-I Binding Protein (AIBP) polypeptide, specifically designed to bind to Toll-like receptor 4 (TLR4), thereby inhibiting TLR4 signaling and reducing pain-associated inflammation.

Benefits of technology

The use of AIBP polypeptides effectively treats, ameliorates, prevents, or decreases the severity or duration of pain-associated diseases and conditions by targeting and inhibiting TLR4-mediated inflammation, providing significant pain relief.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are methods to treat, ameliorate, prevent, reverse, decrease the severity and / or duration of a pain-associated disease or condition comprising parenteral administration of a pharmaceutically acceptable formulation comprising a synthetic or recombinantly modified AP0A1BP (AIBP) polypeptide.
Need to check novelty before this filing date? Find Prior Art